Allergen Immunotherapy Extract

Phase 3Small molecule

JJohns Hopkins University

Allergen Immunotherapy Extract is one of 104 small molecule programs targeting Rhinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

RhinitisActive, not recruiting

Allergic RhinitisActive, not recruiting

Allergic AsthmaCompleted

AsthmaActive, not recruiting

RhinitisPhase 3

Active, not recruiting

Allergic RhinitisPhase 2

Active, not recruiting

Allergic AsthmaPreclinical

Completed

AsthmaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Allergen Immunotherapy Extract

JJohns Hopkins University

Phase 3

1 2

Xolair

Roche

Preclinical

25 3

Cinqair

Teva

Preclinical

13 4

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 5

Atrovent

Boehringer Ingelheim

Preclinical

5 6

Symbicort

AstraZeneca

Preclinical

6 7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 8

Tylenol

KKenvue Brands

Preclinical

1 9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 10

DUPIXENT

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Recruiting

Rhinitis

NCT07348302

Q2 2037

Recruiting

Children

NCT06421415

Clinical

Trials by Indication[1]

Asthma1 trial

Efficacy of Sublingual Versus Subcutaneous Allergen Immunotherapy in Patients With Bronchial Asthma

Completed·MMansoura University Hospital·N/A·NCT05786638·100 enrolled

Children1 trial

Long Term Effect of AIT in Children

Recruiting·OOdense University Hospital··NCT06421415·100 enrolled

Allergic Rhinitis1 trial

A Novel Biologic Therapy for Perennial Allergic Rhinitis

Completed·JJohns Hopkins University·Phase 2·NCT03360071·31 enrolled

Rhinitis1 trial

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

Recruiting·IInmunotek S.L.·Phase 3·NCT07348302·736 enrolled

Allergic Asthma1 trial

Early Changes in Eosinophil Cationic Protein and Sputum Eosinophils Following Subcutaneous Allergen Immunotherapy in Allergic Asthma: A Prospective Cohort Study

Completed·MMansoura University Hospital·Preclinical·NCT07694947·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Allergen Immunotherapy Extract. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allergen Immunotherapy Extract compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allergen Immunotherapy Extract. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJohns Hopkins University

Allergen Immunotherapy Extract

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q2 2037

Trials by Indication[1]

Asthma1 trial

Children1 trial

Allergic Rhinitis1 trial

Rhinitis1 trial

Allergic Asthma1 trial

References

Drug Info

Quick Facts

Related News